Back to results
US 5,312,736 AGranted
Anticoagulant analogues of the tissue factor extrinsic pathway inhibitor (EPI) with reduced affinity for heparin
AssigneeNovo Nordisk A/S
InventorsJesper S. Rasmussen, Ole J. Nordfang
Life of this patent
Estimating the term…
Abstract
Novel extrinsic pathway inhibitors (EPI) are provided wherein one or more of the amino acid residues of native EPI have been deleted. A preferred group of the novel EPI analogues have no or a low heparin binding capacity. The novel EPI analogues can be used for the treatment of patients having coagulation disorders or cancer.
Claims9
An analogue of extrinsic pathway inhibitor (EPI) which analogue is a derivative of the full-length EPI sequence depicted in SEQ ID NO:
- 1, and which analogue retains the anticoagulant activity of native EPI as well as anti-FXa activity, comprises the three Kunitz protease inhibitor domains present in EPI, but has a heparin binding capacity less than 50% of the heparin binding capacity of native EPI when each is contacted with immobilized heparin under physiological conditions.
Dependencies are inferred from the claim text.